Top Markets
Coin of the day
Hillstream BioPharma, Inc. Hillstream BioPharma, Inc.

Hillstream BioPharma, Inc.

HILS
Rankning i aktier #37089
Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed... Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed to creating groundbreaking therapeutic options. Its core mission is to exploit ferroptosis, an anti-cancer pathway that initiates iron-mediated cell death (IMCD), specifically to address cancers that are resistant to conventional treatments. The company's developmental pipeline features several key candidates: HSB-1216: An IMCD inducer currently under development for solid tumor indications. HSB-888: An IMCD inducer incorporating an anthracycline analogue, delivered via a dual Quatramer system, also aimed at solid tumors. HSB-510: A targeted bifunctional inhibitory compound, encapsulated within the Quatramer delivery system, which demonstrates remarkable potency (single-digit nanomolar IC50) against both PI3K-delta and HDAC6, targets recognized for their role in downregulating cellular processes. HSB-114: An immunotherapeutic agent that leverages the proprietary Quatramer technology to precisely deliver the tumor necrosis factor-alpha gene into cancer cells. Established in 2017, the company's operations are based in Bridgewater, New Jersey.
Aktiekurs
$0.181
Senast synkroniserad: 2023-10-20
Marknadsvärde
$2.03M
Förändring (1 dag)
-9.45%
Förändring (1 år)
0.00%
Land
US
Handel Hillstream BioPharma, Inc. (HILS)

Kategori

Utdelningsavkastning för Hillstream BioPharma, Inc. (HILS)
Utdelningsavkastningen (TTM) för Hillstream BioPharma, Inc. (aktiesymbol: HILS) per 2026 är: 0
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.00%
Historik för utdelningsavkastning för Hillstream BioPharma, Inc. (HILS) från 2026 till 2026
Utdelningsavkastning i slutet av varje år (TTM)
År Utdelningsavkastning Ändra
Inte tillräckligt med data för de angivna datumen.
Utdelningsavkastning (TTM) för liknande företag eller konkurrenter